PacBio And GENEWIZ Announce Winner Of The 2017 AACR SMRT Grant

MENLO PARK, Calif. and SOUTH PLAINFIELD, N.J., Nov. 15, 2017 /PRNewswire/ -- Pacific Biosciences of California, Inc. (NASDAQ: PACB), the leader in long-read sequencing, and GENEWIZ, the leading global genomics service provider, announce that Andrew Ludlow, Ph.D. from the University of Michigan, is the winner of the AACR SMRT® Grant. With this SMRT Grant, Dr. Ludlow will receive Iso-Seq® analysis on the PacBio® Sequel® System at the GENEWIZ laboratory to further his investigation to understand the splicing of transcripts regulated by NOVA1 in lung cancer cells.

Isoform sequence (Iso-Seq) analysis is a unique approach to RNA sequencing that produces full-length cDNA sequences without assembly. It is an ideal approach when investigating complex transcriptomes, like human, to discover gene fusions, splice variants, and novel isoforms.

Launched at the annual meeting for the American Association for Cancer Research, the 2017 AACR SMRT Grant is co-sponsored by PacBio and GENEWIZ. The program was open to cancer researchers around the world with the winner being chosen by a panel of scientists. To see a full list of SMRT Grant recipients visit: www.pacb.com/smrtgrant.

PacBio and GENEWIZ have also teamed up on the ASHG SMRT Grant which is open to scientific researchers around the world who are looking to identify and characterize structural variants. Apply by December 11, 2017 at web.genewiz.com/pacbio-sv-grant.

"We are very excited to be partnering with GENEWIZ, one of our newest Sequel platform service providers. Their extensive experience delivering genome and transcriptome solutions to cancer researchers makes them an ideal partner for showcasing the utility of the newly simplified Iso-Seq method for full-length isoform sequencing," said Kevin Corcoran, Senior Vice President of Market Development for PacBio.

"By partnering with top technology providers like PacBio, we are able to bring tens-of-thousands of research scientists around the world access to new and novel technologies like long-read sequencing. It is through this combination of state-of the-art platforms, along with our proprietary approaches and seasoned team of Ph.D.-level staff scientists, that we are helping our customers advance their discoveries faster than ever before," said Dr. Ginger Zhou, Vice President, Global Next Generation Sequencing for GENEWIZ.

For more information about Iso-Seq analysis and the PacBio Sequel platform, visit: www.pacb.com/isoseq

For more information on the GENEWIZ Iso-Seq early access program, visit: genewiz.com/Public/Services/Next-Generation-Sequencing/RNA-Seq

ABOUT PACIFIC BIOSCIENCES

Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT^®) technology, Pacific Biosciences' products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences' technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio^® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.

ABOUT GENEWIZ

GENEWIZ is a global leader in genomics services that enable research scientists within pharmaceutical, biotechnology, agriculture, environmental and clean energy, academic, and government institutions to advance their discoveries. Customers rely on our unique and proprietary genomics technologies and services, backed by our specialized experts in DNA sequencing, gene synthesis, molecular biology, high throughput sequencing, bioinformatics, and GLP regulatory-compliant services.

Headquartered in South Plainfield, NJ, GENEWIZ is privately-held with a network of laboratories in Boston, MA; Washington, D.C. Metro; Research Triangle Park, NC; San Diego, CA; Los Angeles, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, Suzhou, Tianjin, and Guangzhou China; Takeley, United Kingdom; and Tokyo, Japan. For more information, visit www.genewiz.com, and connect with us on LinkedIn, Twitter, Facebook, YouTube, WeChat, and Weibo.

SOURCE GENEWIZ

Related Links

http://www.genewiz.com